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ABSTRACT _
Cardiovascular disease is now the leading causeof death
and disability in our society. Current strategies in the
United States have been very effective in treating the
symptomatic manifestations of severe obstructions but
havedone littleto alter the long-term outcomeof cardio-
vascular disease. Although lipid-lowering therapies have
proven beneficial in secondary prevention for patients
with cardiovascular disease, they are not as widely em-
Cardiovascular disease is the leading cause ofdeath and mortality in the United States today
[1]. It has become a virtual epidemic, claiming the
lives of more women than men each year. It is not a
new problem: organizations have faced this issue for
some time, but its dimensions have increased. In
1925, about 200 people attended the first meeting
of the American Heart Association (AHA) in Atlan-
tic City, New Jersey, where the first papers pre-
sented included: 1) an official method for lessening
heart disease (primary prevention), 2) the care of
adults with moderate heart disorders (secondary
prevention), and 3) the economic aspects of heart
disease. These same issues were widely discussed
among 37,000 attendants at the 1998 meeting of
the AHA, where over 3700 abstracts were pre-
sented. In 1998, the question remains: What can the
AHA or other organized groups of physicians do to
advance the treatment and prevention of cardiovas-
cular disease?
During the past two decades, efforts have been di-
rected toward the treatment of symptomatic mani-
festations of severe obstructions. When one consid-
ers thrombolytic therapy or revascularization, for
example, there is no doubt that technology has im-
proved dramatically. However, these advances
have had only a minor impact on the epidemic of
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ployed in contemporary practiceas they should be. Bet-
ter implementation of lipid-lowering therapies, including
suchmajor issues as cleartreatmentguidelines, physician
and patient compliance, and delivery of healthcare and
qualityof care,must be addressed to shift thinkingabout
the treatment of cardiovascular disease as we advance
into the next century.
cardiovascular disease. A major paradigm shift in
the approach toward treating cardiovascular dis-
ease is necessary. Armed with a body of supporting
data, all reports point to a major effort in the pre-
vention of heart disease.
Current Strategies
With the current approach in the United States fo-
cused on treating the symptomatic manifestation
of severe cardiac obstructions, nearly one million
patients can be expected to be admitted to hospi-
tals this year with acute myocardial infarction and
another million with unstable angina. Three quar-
ters of a million patients will undergo coronary
revascularization. Using this symptomatic lesion
approach, expenses for treating events are increas-
ing annually. In 1995, $136 billion was spent treat-
ing patients with cardiovascular disease. In 1996,
this figure rose to $150 billion, and it is estimated
that, by the year 2000, over $200 billion will be
disbursed [2]. About two-thirds of the $136 billion
spent in 1995 on cardiovascular disease was related
to hospital expenses-mainly directed toward treat-
ment of symptomatic coronary lesions as in acute
myocardial infarction, unstable angina pectoris, and
coronary revascularization-whereas a mere 6%
was spent on medication and lifestyle changes that
could have a significant impact on preventing these
events. Considering that the average age of the US
population is increasing and the financial resources
from the government-the principal entity provid-
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ing care for this population-are dwindling, the
problem is an important societal issue.
Compared with Canada, twice as many coro-
nary arteriograms and more than twice the revascu-
larization procedures are performed in the United
States. In this setting, significantly less disabling an-
gina pectoris was observed in the United States,
mainly because of the greater use of revasculariza-
tion, yet no differences in mortality were detected
[3,4]. Hence, current strategies in the United States
have been very effective in dealing with symptoms
associated with obstructions but have done little to
alter long-term outcomes [5].
Development of aggressive strategies in second-
ary prevention must consider treating the entire dis-
ease process of atherosclerosis rather than focusing
on symptoms associated with severe obstruction. In
one series of studies, major cardiac events were
found to result from obstructions that were less
than 50% stenotic in almost two-thirds of patients;
typically, this type of obstruction is not symptom-
atic [6,7]. In addition, although the likelihood of a
severe obstruction (more than 70% stenotic) lead-
ing to occlusion was higher in these studies, the
number of severe obstructions that resulted in acute
infarction represented less than 15% of all the ma-
jor events observed. Thus, the majority of obstruc-
tions that lead to events significant for the patient,
and are relevant from an economic standpoint, are
those that are less than 50% stenotic. Bearing this
in mind, any strategy to manage the cost of cardio-
vascular disease at the national level must deal with
the disease before the occurrence of symptoms, be-
cause this is where the greatest risk has been shown
to exist [6].
Lipid-Lowering Therapies and
Real Life Practice
Since the Nobel Prize was awarded 12 years ago for
the discovery of low density lipoprotein (LDL) re-
ceptors and statins, lipid-lowering therapy that re-
duces LDL cholesterol by 25-35% has shown signif-
icant benefits in terms of cardiovascular morbidity
and mortality in subjects with elevated cholesterol.
In the Scandinavian Simvastatin Survival Study (4S)
[8] and the West of Scotland study [9], where sub-
jects with total cholesterol levels greater than 275
rng/dl, were treated with a statin, significant reduc-
tions in mortality were observed. These studies sup-
ported treatment from a secondary standpoint in
men, women, the elderly, and diabetics. In almost
every study in this field, benefits of lipid-lowering
therapy were observed rapidly, within 2 years. Rapid
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results are one of the driving forces in managed care.
A large number of people with cardiac events would
benefit from lipid-lowering therapies. Such dramatic
findings prompted the two Nobel laureates, Brown
and Goldstein, to write an editorial entitled "Heart
Attacks Gone with the Century" in Science last year
[10].
However, the sad truth is that lipid-lowering
therapies are not as widely implemented as they
should be [11]. Many have speculated on the impact
of broad lipid-lowering therapy versus revascular-
ization and have suggested the implementation of
more aggressive clinical trials. In a study performed
in the early 1990s among cardiologists, only 18%
of patients with documented coronary disease con-
sulting for cardiac catheterization were on lipid-
lowering therapy. More recently, in the Bypass
Angioplasty Revascularization Investigation (BARI)
trial, which was performed in excellent healthcare
centers, only 10-12% of coronary patients were re-
ceiving a lipid-lowering therapy at the beginning of
the study [12]. After 5 years, only 30-40% of pa-
tients who had had bypass surgery or angioplasty
were receiving a lipid-lowering treatment. Another
study analyzed a database of about 200,000 pa-
tients in over 140 practices throughout the United
States and reported that only 12% of patients were
receiving lipid-lowering therapy [13]. There is suffi-
cient evidence that lipid-lowering therapies are not
fully implemented, and we need to understand why.
Improving Implementation of
Lipid-Lowering Therapies
There are four major issues upon which attention
needs to be focused in order to improve the imple-
mentation of lipid-lowering therapies:
1. An agreement among experts in the field has to
be made to propose some clear recommendations
and guidelines;
2. These recommendations have to be implemented;
3. Patient compliance must be improved;
4. Payment for risk reduction therapies must be
improved.
Guidelines
A consensus statement with nine simple approaches
was developed during a February 1995 meeting of
the AHA Task Force on Secondary Prevention
Strategies, held to consider how to improve the out-
come for patients with cardiovascular disease. The
AHA and the American College of Cardiology have
endorsed these recommendations, which should be
206
posted in every coronary care unit and outpatient
facility. These guidelines include information on
lipid-lowering therapies and also on aspirin, smok-
ing cessation, and diet, among other topics, in a
pocket format. Distributed to over 200,000 health-
care professionals, these guidelines are currently
given to residents throughout the country and a ma-
jor movement is emerging to implement them [14].
Compliance
A significant problem in implementing these guide-
lines is patients' lack of compliance. Various studies
have shown that more than 50% of patients stop
taking their medication after 12 months [15]. There
are many ways whereby physicians and healthcare
providers can improve compliance. Dietary and be-
havioral therapies should be instituted immediately
for patients consulting for a cardiac event with an
LDL cholesterol greater than 100 mgldL. Because
maximal dietary therapy typically reduces LDL
cholesterol by only 15-25 mgldL, a lipid-lowering
pharmacotherapy should be recommended for sub-
jects with an LDL cholesterol level greater than 130
mgldL. Furthermore, to limit patients' confusion,
the cardiovascular specialist or attending physician,
rather than an internist or a family practitioner,
should be responsible for ensuring that appropriate
therapy is initiated and maintained. To achieve the
dramatic results observed in controlled trials such
as the 4S [8], the Cholesterol and Recurrent Events
(CARE) [16], and West of Scotland [9] studies, sup-
port systems that are not available to most health-
care providers need to be developed. Nurse case
management has been shown to be beneficial in the
management of lipid-lowering therapy and postmy-
ocardial infarction risk, as well as in hypertension,
diabetes, and smoking cessation.
Healthcare Systems and Quality ofCare
Academic centers have failed to develop models for
healthcare delivery that successfully integrate pri-
mary care, general medicine, and subspecialty ser-
vices. The distribution of who delivers what ser-
vices is a major issue. The complexity of healthcare
systems, along with the everchanging healthcare
services created by more frequent hospital mergers,
makes the training of residents complex as well.
Managed care is now entering a new era where
quality of care is being considered more seriously.
The National Committee on Quality Assurance
(NCQA) is evaluating managed care organizations
and is rating them. Medical advisory panels of the
NCQA define criteria to evaluate the quality of
care delivered by healthcare organizations. Infor-
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mation related to NCQA evaluation of managed
care organizations is available online. In 1995, over
200 HMOs were reviewed; 25% failed to fulfill
NCQA criteria and were placed on provisional sta-
tus. Such procedures are influencing the way care is
delivered by healthcare organizations, which now
ensure a certain level of quality of care if they want
to maintain clientele. As specialists, it is our role to
advise the NCQA, which, in turn, has the ability to
influence the whole healthcare system for the bene-
fit of society. For example, until last year, only two
criteria were related to cardiovascular disease: beta-
blocker treatment after heart attack and advising
smokers to quit [17]. We have advised the NCQA
on lipid-lowering therapies and cholesterol man-
agement of patients in hospitals, and these items
are now among the eight criteria that relate to car-
diovascular disease.
Finally, a new program in secondary prevention
is being launched by the AHA. Patients who have
had a stroke, heart attack, have suspected heart
disease, or are at high risk for cardiovascular dis-
ease will be able to access educational materials
through an integrated communication system. This
involves patients registering by a telephone system,
marketed through managed care, where their in-
formation is recorded in a database established to
give access to medical and economic information
at a national level.
Conclusions
There is an urgent need to broaden physicians' de-
livery of healthcare to patients with cardiovascular
disease. Emphasis should be placed on prevention
and more resources should be allotted to these ther-
apies. Problems that relate to integrated healthcare
delivery systems need to be understood in order to
move beyond what existed in the 1980s. Educa-
tional prevention and the evaluation of quality of
care will have to be major driving forces in design-
ing systems to take us into the future.
This article was preparedwith the assistance of BioMed-
Com Consultants inc.,Montreal,Canada.
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